financetom
Business
financetom
/
Business
/
Newsletter | M-cap of BSE-listed companies crosses $4 Trillion mark; Charlie Munger dies at 99 & more
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Newsletter | M-cap of BSE-listed companies crosses $4 Trillion mark; Charlie Munger dies at 99 & more
Nov 29, 2023 3:51 AM

Here's a rundown of 11 significant news stories to keep you in the know:

Share Market Live

NSE

#LatestNews⚡

Charlie Munger dies at 99: Here are 10 memorable quotes by the legend on investing and life

"The big money is not in the buying or selling, but in the waiting.” It implies that the most substantial gains in investing aren't typically made by frequently buying and selling stocks or assets in an attempt to time the market or capitalise on short-term fluctuations. Instead, significant wealth accumulation often comes from holding onto quality investments for extended periods, allowing time and the power of compounding to work in favour of the investor.

“A lot of people with high IQs are terrible investors because they’ve got terrible temperaments.”

This quote by Charlie Munger touches upon the notion that intelligence, as measured by IQ, doesn't necessarily correlate with success in investing.

Munger suggested that having a high IQ alone doesn't make someone a good investor. In fact, some exceptionally intelligent individuals may perform poorly in the world of investing due to their behavioral tendencies or temperament.

Market capitalisation of BSE-listed companies crosses $4 trillion mark

The overall market capitalisation of BSE-listed companies crossed the mark of $4 trillion on Wednesday, two-and-a-half years after crossing the $3 trillion mark.

Overall market capitalisation of BSE-listed companies had crossed $3 trillion for the first time on May 24, 2021.

Indian equities have had a stellar run over the last decade, with the Nifty 50 delivering positive annual returns for eight consecutive years. The index has gained 10% for 2023.

IREDA shares list at a 56% premium to IPO price, become second most successful PSU listing in 10 years

The shares of miniratna company Indian Renewable and Energy Development Agency Ltd (IREDA) debuted at a healthy premium of 56% on the exchanges in Wednesday's (November 29) trade. The stock listed at ₹50 on the NSE and the BSE over the IPO price of ₹32 apiece.

With this, the state-run company became the second most successful PSU listing in the last 10 years.

#TechTalks

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Timken Q1 Adjusted Earnings, Net Sales Fall; 2025 Adjusted EPS Guidance Lowered
Timken Q1 Adjusted Earnings, Net Sales Fall; 2025 Adjusted EPS Guidance Lowered
May 25, 2025
07:15 AM EDT, 04/30/2025 (MT Newswires) -- Timken (TKR) reported Q1 adjusted earnings Wednesday of $1.40 per diluted share, down from $1.77 a year earlier. Analysts polled by FactSet expected $1.42. Net sales for the quarter ended March 31 were $1.14 billion, compared with $1.19 billion a year earlier. Analysts surveyed by FactSet expected $1.13 billion. The company reduced its...
Vulcan Materials Q1 Adjusted Earnings, Revenue Rise
Vulcan Materials Q1 Adjusted Earnings, Revenue Rise
May 25, 2025
07:09 AM EDT, 04/30/2025 (MT Newswires) -- Vulcan Materials ( VMC ) reported Q1 adjusted earnings Wednesday of $1 per diluted share, up from $0.80 a year earlier. Analysts polled by FactSet expected $0.77. Revenue for the quarter ended March 31 was $1.64 billion compared with $1.55 billion a year earlier. Analysts surveyed by FactSet expected $1.66 billion. Shares of...
Tradeweb Markets Q1 Adjusted Earnings, Revenue Rise
Tradeweb Markets Q1 Adjusted Earnings, Revenue Rise
May 25, 2025
07:14 AM EDT, 04/30/2025 (MT Newswires) -- Tradeweb Markets ( TW ) reported Q1 adjusted earnings Wednesday of $0.86 per diluted share, up from $0.71 a year earlier. Analysts polled by FactSet expected $0.85. Revenue for the quarter ended March 31 was $509.7 million compared with $408.7 million a year earlier. Analysts surveyed by FactSet expected $512 million. Shares of...
Novartis to buy Regulus Therapeutics for up to $1.7 billion
Novartis to buy Regulus Therapeutics for up to $1.7 billion
May 25, 2025
April 30 (Reuters) - Regulus Therapeutics ( RGLS ) said on Wednesday Swiss drugmaker Novartis has agreed to buy the drug developer for up to $1.7 billion to gain access to its experimental kidney disease drug. ...
Copyright 2023-2025 - www.financetom.com All Rights Reserved